SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Russian Bear who wrote (1212)5/11/1999 5:40:00 PM
From: Andreas Helke  Read Replies (1) of 1826
 
Charles N. Blitzer, MGI PHARMA's president and chief executive officer, said: ''We are pleased to be announcing further evidence that MGI 114 is capable of producing the same kind of anti-tumor response, namely profound tumor shrinkage, in humans that was previously observed in animals. With each step along the development path, we become increasingly enthused about this drug's potential. Now, in addition to strong preclinical evidence of broad spectrum anti-tumor activity, our phase 1 and phase 2 human studies with MGI 114 have thus far produced good indications of anti-cancer activity in prostate, pancreatic and ovarian cancers.''

I wonder why we don't see any contribution of MGI 114 to MOGNs stock price. If there was no MGI 114 MOGN should be worth as much as it is today or even more. I think if MGI 114 completely fails we will see the customary 50% to 75% drop in stock prices and then a slow reversion to the price that is warranted by MOGN profits. 30x 0.25 would give a stock price of $7.50 today. But if MGI 114 turns into a succesful cancer drug MOGN will probably worth much more than 10x todays puny $170 000 000 market cap. For comparison IMNX with one big drug has a market cap of $11 000 000 000.

Andreas
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News